GW Henssler & Associates Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• GW Henssler & Associates Ltd. increased its position in Regeneron Pharmaceuticals by 5.5% during Q2, acquiring 21,482 shares valued at approximately $11.28 million.
• Regeneron Pharmaceuticals reported stellar Q2 earnings of $12.89 EPS, surpassing analyst estimates of $8.43 and achieving a year-over-year revenue growth of 3.6% with earnings of $3.68 billion.
• The company also announced a quarterly dividend of $0.88 per share, reflecting an annualized yield of 0.6%, while the dividend payout ratio is currently at 8.87%.

GW Henssler & Associates Ltd. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,482 shares of the biopharmaceutical company's stock after purchasing an additional 1,122 shares during the quarter. GW Henssler & Associates Ltd.'s holdings in Regeneron Pharmaceuticals were worth $11,278,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Meritage Portfolio Management purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $6,014,000. CWM LLC raised its stake in shares of Regeneron Pharmaceuticals by 770.0% in the second quarter. CWM LLC now owns 35,506 shares of the biopharmaceutical company's stock worth $18,641,000 after purchasing an additional 31,425 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 7.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 10,853 shares of the biopharmaceutical company's stock worth $5,699,000 after purchasing an additional 792 shares during the last quarter. Concurrent Investment Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 136.4% in the second quarter. Concurrent Investment Advisors LLC now owns 1,622 shares of the biopharmaceutical company's stock worth $852,000 after purchasing an additional 936 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 11.3% in the second quarter. Fifth Third Wealth Advisors LLC now owns 1,511 shares of the biopharmaceutical company's stock worth $793,000 after purchasing an additional 154 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $564.63 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business has a fifty day simple moving average of $573.95 and a two-hundred day simple moving average of $564.51. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,024.36. The company has a market capitalization of $59.84 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the business posted $11.56 earnings per share. The business's revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research report on Monday, August 4th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Finally, UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $817.46.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.